Results 81 to 90 of about 8,127 (167)

Ribociclib plus Endocrine Therapy in Early Breast Cancer

Background Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.
Chakravartty, Arunava, Lipatov, Oleg, Nowecki, Zbigniew, Ghaznawi, Farhat, Severin, Irene, Hortobagyi, Gabriel, Stroyakovskiy, Daniil, Barrios, Carlos, Yardley, Denise A., Afenjar, Karen, McAndrew, Nicholas, Fresco, Rodrigo, Li, Zheng, Kukielka-Budny, Bozena, Hurvitz, Sara, Slamon, Dennis, Crown, John, Ji, Yan, Huang, Chiun-Sheng, Ruiz-Borrego, Manuel, Chia, Stephen, Loi, Sherene, Fasching, Peter A., Xu, Binghe, Taran, Tetiana, Bardia, Aditya, Untch, Michael, Im, Seock-Ah, Moroose, Rebecca, Visco, Frances, Zarate, Juan P.   +30 more
core   +1 more source

Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort

Medicina
Background and Objectives: Endocrine therapy combined with CDK4/6 inhibitors are widely recognized as the standard first-line approach for treating hormone receptor-positive HER2-negative (HR+/HER2−) metastatic breast cancer (mBC). Nonetheless, potential
Enes Erul, Nejat Emre Öksüz, Erman Akkus, Pınar Kubilay Tolunay, Elif Berna Köksoy, Hatime Arzu Yasar   +5 more
doaj   +1 more source

The effect of ribociclib on the expression levels of miR-141 and CDK4/6-USP51 signaling pathway genes in MCF-7 and MDA-MB-231 cells.

PLoS ONE
IntroductionPatients with breast cancer, especially triple-negative breast cancer, have a poor prognosis. There is still no effective treatment for this disease.
Shayeste Sadat Baghermanesh, Mahmood Barati, Arshad Hosseini   +2 more
doaj   +1 more source

A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia

Diseases
Background: Cutaneous toxicities associated with CDK4/6 inhibitors are uncommon but may affect treatment adherence. We present the case of a patient with advanced breast cancer who developed vitiligo-like lesions after initiating ribociclib, contributing
John Fernando Montenegro, Giovanna Patricia Rivas-Tafurt, Sinthia Vidal-Cañas, Miguel Ángel Diaz-Diaz, Cesar Eduardo Bermudez, Daniel Florez, Andres Felipe Bravo-Gustin, Yamil Liscano   +7 more
doaj   +1 more source

METHOD OF PREPARING CRYSTALLINE FORM A OF RIBOCICLIB SUCCINATE

Ribociclib is a kinase inhibitor. The active pharmaceutical ingredient Ribociclib is developed in the form of its succinate salt to improve physicochemical stability, manufacturability, and solid‑state consistency.
Anonymous
core   +1 more source

Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma

, 2018
Ribociclib is a specific cyclin dependent kinase (Cdk) 4/6 inhibitor that induces G1 arrest by blocking the formation of cyclin D1-Cdk4/6 complex and inhibiting retinoblastoma (RB) phosphorylation. Cyclin D1 is overexpressed in over 90% of nasopharyngeal
Connie W. C. Hui, Kwok-Wai Lo, Brigette B. Y. Ma, Chi-Hang Wong, Edwin P. Hui, Anthony T. C. Chan   +5 more
core   +1 more source

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database

Frontiers in Pharmacology
IntroductionCyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are first-line treatments for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. With their increasing clinical use, infection-related adverse events (
Jinhua Chen, Linlin Tang, Wenping Song, Cuicui Sun, Wenzhou Zhang   +4 more
doaj   +1 more source

Ribociclib Approved for Advanced Breast Cancer

, 2017
The FDA has approved ribociclib combined with aromatase inhibitor therapy for women with metastatic HR-positive, HER2-negative breast cancer. It is the second CDK 4/6 inhibitor approved for these patients, behind palbociclib; a third is under ...

core   +1 more source

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors

BJC Reports
Background Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT).
Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal, Wen Wee Ma, Yanyan Lou, Grace K. Dy, Amit Mahipal, S. John Weroha, Andrea E. Wahner Hendrickson, Joel M. Reid, Alex A. Adjei   +12 more
doaj   +1 more source

Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2

Journal of Comparative Effectiveness Research
Aim: The eligibility criteria of randomized controlled trials can exclude groups of patients indicated for the therapy post-approval and the trial populationmay not be generalizable to routine care.We attempted to emulate the MONALEESA-2 trial of ...
Amanda M Kong, Dionna Andrean, Saarah Khan, Julia Choi, Ronac Mamtani, Ravi Parikh, Ashley Jaksa, Ulka Campbell   +7 more
doaj   +1 more source